Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle
Résumé
Highlights Development and characterization of a Huh7 cell line with high expression of hNTCP. Identification of three FDA approved therapeutics with antiviral effect against HDV. We support the relationship between hNTCP metabolic and viral receptor function. Abstract Worldwide there are approximately 240 million individuals chronically infected with the hepatitis B virus (HBV), including 15–20 million coinfected with the hepatitis delta virus (HDV). Treatments available today are not fully efficient and often associated to important side effects and development of drug resistance. Targeting the HBV/HDV entry step using preS1-specific lipopeptides appears as a promising strategy to block viral entry for both HBV and HDV (Gripon et al., 2005; Petersen et al., 2008). Recently, the human Sodium Taurocholate Cotransporting Polypeptide (hNTCP) has been identified as a functional, preS1-specific receptor for HBV and HDV. This groundbreaking discovery has opened a very promising avenue for the treatment of chronic HBV and HDV infections. Here we investigated the ability of FDA approved therapeutics with documented inhibitory effect on hNTCP cellular function to impair viral entry using a HDV in vitro infection model based on a hNTCP-expressing Huh7 cell line. We demonstrate the potential of three FDA approved molecules, irbesartan, ezetimibe, and ritonavir, to alter HDV infection in vitro.
Fichier principal
Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle.pdf (436.79 Ko)
Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
